PapersFlow Research Brief

Pharmaceutical studies and practices
Research Guide

What is Pharmaceutical studies and practices?

Pharmaceutical studies and practices is the interdisciplinary body of research and professional activity that develops, evaluates, regulates, and uses medicines through laboratory standards, pharmacology, clinical testing, safe prescribing, pharmacokinetics, and patient-centered medication management.

Pharmaceutical studies and practices spans core scientific foundations (e.g., receptor antagonism quantification in "SOME QUANTITATIVE USES OF DRUG ANTAGONISTS" (1959) and drug disposition modeling in "Pharmacokinetics" (1982)) and applied clinical guidance (e.g., "Harrison's Principles of Internal Medicine." (1988) and "The Pharmacological Basis of Therapeutics" (1976)). Medication-use quality and safety are central themes, including adherence (Osterberg and Blaschke (2005) in "Adherence to Medication"; De Geest and Sabaté (2003) in "Adherence to Long-Term Therapies: Evidence for Action") and adverse drug reactions (Lazarou et al. (1998) in "Incidence of Adverse Drug Reactions in Hospitalized Patients"). The provided corpus metadata lists 116,976 works for this topic, with a 5-year growth rate reported as N/A.

117.0K
Papers
N/A
5yr Growth
712.4K
Total Citations

Research Sub-Topics

Why It Matters

Pharmaceutical studies and practices directly affects patient outcomes by determining whether medicines are selected appropriately, used safely, and taken as intended. Adherence is a concrete example: Osterberg and Blaschke (2005) in "Adherence to Medication" argued that “the full benefit of many effective medications will be achieved only if patients adhere to prescribed treatment regimens,” framing adherence as a practical determinant of effectiveness rather than a purely behavioral label. Drug safety is another high-impact application area: Lazarou, Pomeranz, and Corey (1998) in "Incidence of Adverse Drug Reactions in Hospitalized Patients" concluded that the incidence of serious and fatal adverse drug reactions (ADRs) in US hospitals was “extremely high,” positioning ADR monitoring and prevention as a core clinical and health-system priority. Standardization underpins both efficacy and safety; Bruck (1980) in "National Committee for Clinical Laboratory Standards" described the National Committee for Clinical Laboratory Standards (NCCLS) as a valuable organization with structured membership, highlighting how laboratory standards support reliable diagnostics and therapeutic monitoring that inform prescribing decisions. At the methodological level, "SOME QUANTITATIVE USES OF DRUG ANTAGONISTS" (1959) provided quantitative receptor-based tools (pAx) for comparing antagonists and identifying shared receptor mechanisms, while "Pharmacokinetics" (1982) established concepts used to design dosing regimens and interpret concentration–time behavior in clinical settings.

Reading Guide

Where to Start

Start with Osterberg and Blaschke’s "Adherence to Medication" (2005) because it frames a widely encountered, practice-facing problem (medication-taking behavior) in clear clinical terms and motivates why pharmaceutical practice must address implementation barriers, not only drug choice.

Key Papers Explained

Mechanistic and measurement foundations begin with Arunlakshana and Schild’s "SOME QUANTITATIVE USES OF DRUG ANTAGONISTS" (1959), which provides a quantitative receptor-competition framework (pAx) for comparing antagonists. Dosing and concentration–time reasoning is then systematized in Gibaldi and Perrier’s "Pharmacokinetics" (1982), which supplies concepts used when translating pharmacology into practical regimens. These scientific foundations connect to broad therapeutic decision-making in "The Pharmacological Basis of Therapeutics" (1976) and "Harrison's Principles of Internal Medicine." (1988), which situate drug mechanisms and dosing within disease management. Practice quality and outcomes are emphasized by Lazarou et al.’s "Incidence of Adverse Drug Reactions in Hospitalized Patients" (1998) and by adherence-focused syntheses in "Adherence to Long-Term Therapies: Evidence for Action" (2003) and "Adherence to Medication" (2005), which together highlight that safety and effectiveness depend on both system performance and patient experience.

Paper Timeline

100%
graph LR P0["ECDEU Assessment Manual for Psyc...
1976 · 8.8K cites"] P1["The Pharmacological Basis of The...
1976 · 8.2K cites"] P2["National Committee for Clinical ...
1980 · 14.8K cites"] P3["Harrison's Principles of Interna...
1988 · 12.6K cites"] P4["Adherence to Long-Term Therapies...
2003 · 6.3K cites"] P5["Arzneimittelforschung
2005 · 9.4K cites"] P6["Adherence to Medication
2005 · 7.8K cites"] P0 --> P1 P1 --> P2 P2 --> P3 P3 --> P4 P4 --> P5 P5 --> P6 style P2 fill:#DC5238,stroke:#c4452e,stroke-width:2px
Scroll to zoom • Drag to pan

Most-cited paper highlighted in red. Papers ordered chronologically.

Advanced Directions

Advanced work in pharmaceutical studies and practices, as reflected by the most-cited core literature provided, centers on integrating (i) standardized measurement and laboratory procedures ("National Committee for Clinical Laboratory Standards" (1980)), (ii) quantitative pharmacology and pharmacokinetics ("SOME QUANTITATIVE USES OF DRUG ANTAGONISTS" (1959); "Pharmacokinetics" (1982)), and (iii) real-world medication-use outcomes such as adherence and ADRs ("Adherence to Medication" (2005); "Incidence of Adverse Drug Reactions in Hospitalized Patients" (1998)). A practical frontier is building medication-use systems that simultaneously optimize regimen design, detect preventable harms, and support long-term use, aligning the safety signal from Lazarou et al. (1998) with the implementation focus from Osterberg and Blaschke (2005).

Papers at a Glance

# Paper Year Venue Citations Open Access
1 National Committee for Clinical Laboratory Standards 1980 PEDIATRICS 14.8K
2 Harrison's Principles of Internal Medicine. 1988 Annals of Internal Med... 12.6K
3 Arzneimittelforschung 2005 Bundesgesundheitsblatt... 9.4K
4 ECDEU Assessment Manual for Psychopharmacology 1976 Internet Archive (Inte... 8.8K
5 The Pharmacological Basis of Therapeutics 1976 American Journal of He... 8.2K
6 Adherence to Medication 2005 New England Journal of... 7.8K
7 Adherence to Long-Term Therapies: Evidence for Action 2003 European Journal of Ca... 6.3K
8 Incidence of Adverse Drug Reactions in Hospitalized Patients 1998 JAMA 4.8K
9 Pharmacokinetics 1982 4.1K
10 SOME QUANTITATIVE USES OF DRUG ANTAGONISTS 1959 British Journal of Pha... 4.0K

In the News

Code & Tools

Recent Preprints

Latest Developments

Recent developments in pharmaceutical studies and practices as of February 2026 highlight significant advances in drug development, including the use of New Approach Methodologies (NAMs) and regulatory changes aimed at speeding up and improving safety (drugtargetreview.com). The industry is also focusing on scientific breakthroughs such as cell-free biomanufacturing systems (cas.org), and there is ongoing research into innovative therapies like oral semaglutide for high-risk type 2 diabetes (nejm.org). Additionally, the industry faces external challenges related to regulatory and geopolitical volatility, while technological innovations, including AI, continue to shape research and development practices (zs.com).

Frequently Asked Questions

What is meant by pharmaceutical studies and practices in academic research?

Pharmaceutical studies and practices is the combined study of how medicines are discovered and characterized, how their effects are measured and modeled, and how they are used in real clinical workflows. The provided literature anchors this from mechanistic quantification ("SOME QUANTITATIVE USES OF DRUG ANTAGONISTS" (1959)) through dosing science ("Pharmacokinetics" (1982)) to clinical guidance ("Harrison's Principles of Internal Medicine." (1988)).

How do researchers quantify and compare drug antagonists in pharmacology?

Arunlakshana and Schild (1959) in "SOME QUANTITATIVE USES OF DRUG ANTAGONISTS" discussed applications of pAx measurements under a mass-law competition hypothesis, using pAx to identify agonists acting at the same receptors and to compare receptor antagonists. This provides a quantitative framework for mechanism-based comparison rather than relying only on qualitative pharmacologic descriptions.

How is pharmacokinetics used to guide dosing and therapeutic decisions?

"Pharmacokinetics" (1982) formalized pharmacokinetic concepts used to interpret drug concentration–time relationships and supports dose selection and adjustment in clinical practice. In applied medicine, such dosing logic is integrated into broader clinical decision-making described in "Harrison's Principles of Internal Medicine." (1988) and drug-therapy references such as "The Pharmacological Basis of Therapeutics" (1976).

Why is medication adherence treated as a core problem in pharmaceutical practice?

Osterberg and Blaschke (2005) in "Adherence to Medication" stated that the full benefit of many effective medications is achieved only when patients adhere to prescribed regimens and cautioned that labeling patients as “noncompliant” can be stigmatizing. De Geest and Sabaté (2003) in "Adherence to Long-Term Therapies: Evidence for Action" further positioned adherence as a long-term therapy issue requiring evidence-informed action rather than a one-time counseling message.

Which evidence highlights the clinical importance of adverse drug reactions in hospitals?

Lazarou, Pomeranz, and Corey (1998) in "Incidence of Adverse Drug Reactions in Hospitalized Patients" reported that serious and fatal ADR incidence in US hospitals was extremely high, while also noting heterogeneity among studies and potential small sample biases. The paper’s conclusion supports prioritizing ADR detection, prevention, and medication safety systems as central components of pharmaceutical practice.

Which foundational references are commonly used to connect pharmacology to bedside practice?

"The Pharmacological Basis of Therapeutics" (1976) is a core pharmacology reference linking drug mechanisms to therapeutic use, and "Harrison's Principles of Internal Medicine." (1988) is a broad clinical medicine reference integrating pharmacotherapy across organ systems. For psychopharmacology assessment methods, Guy (1976) compiled "ECDEU Assessment Manual for Psychopharmacology," which is frequently cited in contexts that require standardized evaluation approaches.

Open Research Questions

  • ? How can adherence interventions be designed to improve real-world medication-taking without stigmatizing patients, consistent with the concerns raised in "Adherence to Medication" (2005)?
  • ? Which hospital processes most effectively reduce the burden of serious and fatal ADRs highlighted as “extremely high” in "Incidence of Adverse Drug Reactions in Hospitalized Patients" (1998)?
  • ? How can receptor-based quantitative measures such as pAx be integrated with clinical pharmacokinetic reasoning to improve drug selection and dose optimization across patient subgroups?
  • ? What minimal laboratory standardization elements (as implied by the role of NCCLS in "National Committee for Clinical Laboratory Standards" (1980)) most strongly improve the reliability of therapeutic monitoring and downstream prescribing decisions?

Research Pharmaceutical studies and practices with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching Pharmaceutical studies and practices with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.